Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-92
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-34
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3
   PubMed Web of Science ®Google Scholar
• Mandanas RA, Leibowitz DS, Gharehbaghi K, et al. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993;82:1838-47
   PubMed Web of Science ®Google Scholar
• Okuda K, Matulonis U, Salgia R, et al. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994;22:1111-17
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53
   PubMed Web of Science ®Google Scholar
• Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995;92:11746-50
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70:901-10
   PubMed Web of Science ®Google Scholar
• Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811-20
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Deininger M, OBSG Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:abstract 1126
   Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-203
   PubMed Web of Science ®Google Scholar
• Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-81
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477-85
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567-76
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403-12
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486-92
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Contr 2009;16:122-31
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-9
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006;20:1061-6
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Santini V, et al. Homoharringtonine: history, current research, and future direction. Cancer 2001;92:1591-605
   PubMed Web of Science ®Google Scholar
• Powell RG, Weisleder D, Smith CR Jr., Rohwedder WK. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett 1970;11:815-18
   Google Scholar
• Powell RG, Weisleder D, Smith CR Jr. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 1972;61:1227-30
   PubMed Web of Science ®Google Scholar
• Hospital CPsLAt. Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chin Med J (Engl) 1977;3:319-24
   PubMedGoogle Scholar
• Group CRC. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J (Engl) 1976;2:263-72
   PubMedGoogle Scholar
• O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322-6
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999;93:4149-53
   PubMed Web of Science ®Google Scholar
• Gurel G, Blaha G, Moore PB, Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 2009;389:146-56
   PubMed Web of Science ®Google Scholar
• Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977;12:298-300
   PubMed Web of Science ®Google Scholar
• Visani G, Russo D, Ottaviani E, et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on ‘in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 1997;11:624-8
   PubMed Web of Science ®Google Scholar
• Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006;5:723-31
   PubMed Web of Science ®Google Scholar
• Allan EK, Holyoake TL, Craig AR, Jorgensen HG. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 2011;25:985-94
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Michaels S, et al. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446-54
   PubMed Web of Science ®Google Scholar
• Lou YJ, Qian WB, Jin J. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma 2007;48:1400-6
   PubMed Web of Science ®Google Scholar
• Kuroda J, Kamitsuji Y, Kimura S, et al. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol 2008;87:507-15
   PubMed Web of Science ®Google Scholar
• Zhou JY, Chen DL, Shen ZS, Koeffler HP. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990;50:2031-5
   PubMed Web of Science ®Google Scholar
• Tong H, Ren Y, Zhang F, Jin J. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Eur J Haematol 2008;81:259-66
   PubMed Web of Science ®Google Scholar
• Ni D, Ho DH, Vijjeswarapu M, et al. Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol 2003;3:47-52
   PubMedGoogle Scholar
• Lu K, Savaraj N, Feun LG, et al. Pharmacokinetics of homoharringtonine in dogs. Cancer Chemother Pharmacol 1988;21:139-42
   PubMed Web of Science ®Google Scholar
• Levy V, Zohar S, Bardin C, et al. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006;95:253-9
   PubMed Web of Science ®Google Scholar
• Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977;72:323-30
   PubMedGoogle Scholar
• Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 2004;76:199-204
   PubMed Web of Science ®Google Scholar
• Tipping AJ, Mahon FX, Zafirides G, et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002;16:2349-57
   PubMed Web of Science ®Google Scholar
• Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999-2007
   PubMed Web of Science ®Google Scholar
• Scappini B, Onida F, Kantarjian HM, et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 2002;94:2653-62
   PubMed Web of Science ®Google Scholar
• Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006;66:10959-66
   PubMed Web of Science ®Google Scholar
• Jin W, Wu J, Zhuang Z, et al. Gene expression profiling in apoptotic k562 cells treated by homoharringtonine. Acta Biochim Biophys Sin (Shanghai) 2007;39:982-91
   PubMed Web of Science ®Google Scholar
• Michaels S, Brown D, Segal D. Analysis of transcription factor expression after homoharringtonine treatment. Proc Amer Assoc Cancer Res 2007;48:abstract 4843
   Google Scholar
• Klag T, Hartel N, Erben P, et al. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common beta-subunit c of cytokine receptors. Leukemia 2012;26:1321-8
   PubMedGoogle Scholar
• Legha SS, Keating M, Picket S, et al. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984;68:1085-91
   PubMedGoogle Scholar
• Neidhart JA, Young DC, Derocher D, Metz EN. Phase I trial of homoharringtonine. Cancer Treat Rep 1983;67:801-4
   PubMedGoogle Scholar
• Coonley CJ, Warrell RP Jr., Young CW. Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep 1983;67:693-6
   PubMedGoogle Scholar
• Stewart JA, Krakoff IH. Homoharringtonine: a phase I evaluation. Invest New Drugs 1985;3:279-86
   PubMed Web of Science ®Google Scholar
• Neidhart JA, Young DC, Kraut E, et al. Phase I trial of homoharringtonine administered by prolonged continuous infusion. Cancer Res 1986;46:967-9
   PubMed Web of Science ®Google Scholar
• Whitacre M, Van Echo DA, Applefeld Met al.. Phase I study of homoharringtonine (NSC 141-633). Proc Am Soc Clin Oncol 1985;2:abstract
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-55
   PubMed Web of Science ®Google Scholar
• O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002;94:2024-32
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Smith TL, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000;18:3513-21
   PubMed Web of Science ®Google Scholar
• Ernst T, Vance E, Alyea E III, et al. Homoharringtonine and low-dose ara-C is a highly effective combination for the treatment of CML in chronic phase. Blood 1997;90:abstract p571a
   Google Scholar
• Stone RM, Donohue KA, Stock W, et al. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009;63(5):859-64
   PubMedGoogle Scholar
• Cortes J, Digumarti R, Parikh PM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 2013;88(5):350-4
   PubMed Web of Science ®Google Scholar
• Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120:2573-80
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim D-W, Pinilla-Ibarz J, et al. Pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. Blood (ASH Annual Meeting Abstracts) 2012;120:163
   Web of Science ®Google Scholar
• O'Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003;98:888-93
   PubMed Web of Science ®Google Scholar
• Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850-5
   PubMed Web of Science ®Google Scholar
• Li YF, Liu X, Liu DS, et al. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy. Leuk Lymphoma 2009;50:1889-91
   PubMed Web of Science ®Google Scholar
• Fang B, Li N, Song Y, et al. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Ann Hematol 2010;89:1099-105
   PubMed Web of Science ®Google Scholar